Evidence map›Paper›PMID 35704275›Full record

ArticleNMR in biomedicine2023

Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors.

Nicholas S Cho, Akifumi Hagiwara, Jingwen Yao, David A Nathanson, Robert M Prins, Chencai Wang, Catalina Raymond, Brandon R Desousa, Ajit Divakaruni, Danielle H Morrow and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NMR in biomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Multinuclear Interleaving ofNMR in biomedicine · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Nicholas S ChoUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-8686-0575
Akifumi HagiwaraUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California, USA.
Jingwen YaoUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California, USA.
David A NathansonDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Robert M PrinsDepartment of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Chencai WangUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California, USA.
Catalina RaymondUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California, USA.
Brandon R DesousaDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Ajit DivakaruniDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Danielle H MorrowDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Phioanh L NghiemphuDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Albert LaiDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Linda M LiauDepartment of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Richard G EversonDepartment of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Noriko SalamonDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Whitney B PopeDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Timothy F CloughesyDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-2764-6640
University of California, Los Angeles · US

Funding

UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Metabolic MRI for quantifying aerobic glycolysis and immune function in gliomasR21CA223757 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ELLINGSON, BENJAMIN M. · 2018 to 2019
$366k
NCI NIH HHS P50 CA211015NCI NIH HHS R21 CA223757
6 · The paper itself

Abstract

Amine-weighted chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) is particularly valuable as an amine- and pH-sensitive imaging technique in brain tumors, targeting the intrinsically high concentration of amino acids with exchangeable amine protons and reduced extracellular pH in brain tumors. Amine-weighted CEST MRI contrast is dependent on the glioma genotype, likely related to differences in degree of malignancy and metabolic behavior. Amine-weighted CEST MRI may provide complementary value to anatomic imaging in conventional and exploratory therapies in brain tumors, including chemoradiation, antiangiogenic therapies, and immunotherapies. Continual improvement and clinical testing of amine-weighted CEST MRI has the potential to greatly impact patients with brain tumors by understanding vulnerabilities in the tumor microenvironment that may be therapeutically exploited.

Indexed as

AminesBrain NeoplasmsHumansHydrogen-Ion ConcentrationMagnetic Resonance ImagingProtonsTumor MicroenvironmentAminesProtonsAmine CESTBrain TumorCEST EPIGlioblastomapH ImagingTreatment Response

Identifiers

PMID35704275
PMCPMC13030910
OpenAlexW4282971147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.